Investor Presentaiton
Investor Presentation
First nine months of 2018
Slide 43
Growth opportunities supported by strong global presence
in both sales and manufacturing
Employees in sales regions¹
Global manufacturing setup
Denmark (~9,000 employees)
Diabetes and biopharmaceutical
API production
Filling and packaging
Moulding and assembly
Tablet production
Kaluga, Russia
(~266 employees)
Filling
Assembly
Packaging
North America Operations:
~4,700
Region AAMEO:
West Lebanon, NH, USA
(~188 employees)
~4,700
Biopharmaceutical
API production
Region China:
~3,200
Region Europe:
~2,900
Region Japan & Korea:
~1,200
Region Latin America:
~970
Koriyama, Japan
(~70 employees)
Packaging
Clayton, NC, USA
(~1,186 employees)
Diabetes API production
Filling
Assembly
Packaging of above
Chartres, France
(~1,140 employees)
Filling
Assembly
Packaging
Tianjin, China
(~1,045 employees)
Filling
Assembly
Packaging
Montes Claros, Brazil
(~980 employees)
Tizi Ouzou, Algeria
(~240 employees)
Total non-HQ/manufacturing employees: ~19,000¹
Filling
Assembly
Packaging
Tablet production
1 Employees represent full-time equivalents in Novo Nordisk's sales regions (excludes all other employees in headquarter, research sites and manufacturing sites) as of September 2018
AAMEO: Africa, Asia, the Middle-East and Oceania.
changing
diabetes®
novo nordiskView entire presentation